Human ERBB2 Stable Cell Line - MC38

The ERBB2 gene, also known as HER2 or neu, encodes a member of the epidermal growth factor receptor family of receptor tyrosine kinases. Located on chromosome 17q12, this protein lacks its own ligand-binding domain but heterodimerizes with other ligand-bound EGFR family members to activate downstream signaling pathways including MAPK and PI3K/AKT. Amplification or overexpression of ERBB2 is a well-established driver in multiple cancers, particularly breast, ovarian, and gastric tumors, making it one of the most clinically relevant therapeutic targets in oncology. The Human ERBB2 Stable Cell Line - MC38 is a murine colon adenocarcinoma cell line engineered to stably express full-length human ERBB2 (HER2) on the cell surface. MC38 is widely used in preclinical research because it is derived from C57BL/6 mice and forms solid tumors with an intact immune microenvironment, making it compatible with syngeneic mouse models.

This cell line serves as a versatile tool for a range of applications in cancer biology and drug development. It is particularly valuable for evaluating the efficacy of HER2-targeted therapeutics, including monoclonal antibodies such as trastuzumab and pertuzumab, antibody-drug conjugates, bispecific antibodies, and CAR-T cell therapies. Because the MC38 background is immunocompetent, researchers can also assess immune-mediated mechanisms of tumor clearance, including antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and T cell activation, in a way that is not possible with xenograft models. The line is suitable for both subcutaneous and orthotopic tumor implantation studies, enabling longitudinal monitoring of tumor growth and response to treatment. Additionally, it can be used to investigate mechanisms of resistance to HER2-targeted agents, combination therapy strategies, and biomarker discovery. The stable and consistent expression of human ERBB2 ensures reproducibility across experiments, making it a reliable platform for preclinical validation of novel HER2-directed therapies before advancing into clinical trials.